# BDC Healthcare Venture

> BDC Healthcare Venture is a VC fund backing Biotechnology and Health Care. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montréal, Canada
- Total investments: 14
- Last investment: Jun 2017
- Lead investor: 21%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bdc/
- X (Twitter): https://twitter.com/bdc_ca
- Website: http://www.bdc.ca/EN/bdc-capital/venture-capital/strategic-approach/Pages/health-venture-fund.aspx
- Facebook: https://www.facebook.com/BDC.ca/

BDC Healthcare Venture is a venture capital firm specializes in healthcare investments. The firm prefers to invest in the innovative therapeutics, medical technology, health technology, prevention, diagnostics, personalized treatment, mobile technologies and services, robotics, automation and disease management sectors.

## Contacts

5 contacts available for BDC Healthcare Venture. Shizune tracks 6 team members at BDC Healthcare Venture. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bdc-healthcare-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8M–$68M |
| Series B | $4.7M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 57% |
| Health Care | 7 | 50% |
| Therapeutics | 4 | 29% |
| Medical Device | 4 | 29% |
| Biopharma | 2 | 14% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 36% |
| Series A | 4 | 29% |
| Funding Round | 2 | 14% |
| Series D | 1 | 7% |
| Convertible Note | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Amine Benmoussa | Principal | 2 | https://shizune.co/investors/profile/amine-benmoussa |
| Dion Madsen | Senior Managing Partner | 12 | https://shizune.co/investors/profile/dion-madsen |
| Allyson Tighe | Analyst, Healthcare Venture Fund | 1 | https://shizune.co/investors/profile/allyson-tighe |
| Bharat Srinivasa | Analyst, Healthcare Venture Fund | 5 | https://shizune.co/investors/profile/bharat-srinivasa |
| Ela Borenstein | Managing Partner | 4 | https://shizune.co/investors/profile/ela-borenstein |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PHEMI | The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $10M | Series B | Jun 27, 2017 |  |
| Repare Therapeutics | Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancertreatment both with single therapy and in combination with existing drugs and treatments. | $68M | Series A | Jun 22, 2017 |  |
| PHEMI | The PHEMI Trustworthy Health DataLab is a unique, cloud-based, integrated big data management system that allows healthcare organizations to enhance innovation and generate value from healthcare data by simplifying the ingestion and de-identification of data with NSA/military-grade governance, privacy, and security built-in.Conventionalproducts simply lock down data, PHEMI goes further, solving privacy and security challenges and addressing the urgent need to secure, govern, curate, and control access to privacy-sensitive personal healthcare information (PHI). This improves data sharing and collaboration inside and outside of an enterprise—without compromising the privacy of sensitive information or increasing administrative burden.Built on privacy-by-design principles, the software gives researchers, scientists, and clinicians faster access to more information while ensuring that they only see data on a need-to-know basis. Responsible data sharing and a governance framework facilitate compliance with privacy regulations.PHEMI Trustworthy Health DataLab can scale to any size of organization, is easy to deploy and manage, connects to hundreds of data sources, and integrates with popular data science and business analysis tools.For more information, visit https://www.phemi.com/ and follow us on Twitter @PHEMISystems, Linkedin, Youtube, and Facebook | $8.7M | Series A | Aug 11, 2015 |  |
| Xagenic | Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation.This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples.We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results. | $10.8M | Series B | Jul 09, 2015 |  |
| Clementia Pharmaceuticals | Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shownpotent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues.Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec. | $60M |  | Jun 23, 2015 |  |
| Milestone Pharmaceuticals | Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $17M | Series B | Jun 15, 2015 |  |
| Profound Medical Inc | The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $20.1M |  | Apr 30, 2015 |  |
| Thrasos | Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has apreclinical development program for treating chronic kidney disease (CKD). | $21M | Series D | Mar 31, 2015 |  |
| Profound Medical Inc | The Profound Medical team is committed to creating the powerful combination of real-time MR-guidance as the imaging platform and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. These key technology pillars, linked with intelligent software and robotics, have the potential to fulfill unmet needs of patientsand clinicians in many anatomies and disease states, including prostate cancer, uterine fibroids, and bone metastases. Our mission is to profoundly change the standard of care by creating a tomorrow where clinicians can confidently ablate tissue with precision; a tomorrow where patients have access to safe and effective treatment options, so they can quickly return to their daily lives. | $1.1M | Convertible Note | Jan 27, 2015 |  |
| Interface Biologics | Interface Biologics, Inc. (IBI) is a commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their patent-protected technologies include anti-thrombogenic additives for blood contacting medical devices and polymer enabled combination drug delivery devices.IBI has exclusive Endexo™ technology licensing agreements with AngioDynamics for vascular access catheters and with Fresenius Medical Care for chronic dialysis systems. AngioDynamics’ BioFlo PICCS, Ports and DuraMax Dialysis Catheter with IBI’s Endexo technology have received FDA clearance and are gaining commercial traction. IBI also has a joint venture commercial agreement with Qualimed to develop a drug-coated balloon based on IBI’s Kinesyx™ technology. The company was founded in 2001 and is headquartered in Toronto, Canada at the acclaimed MaRS Innovation Centre. |  | Series B | Jan 13, 2015 |  |

10 of 14 investments shown.

## Co-investors
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 3 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Pappas Ventures](https://shizune.co/investors/profile/pappas-ventures) — VC Fund, 2 deals together
- [Yaletown Partners](https://shizune.co/investors/profile/yaletown-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Canada](https://shizune.co/investors/health-care-vc-funds-canada)
- [Biotech Investors in Canada](https://shizune.co/investors/biotech-investors-canada)
- [Biotech VC Funds in Canada](https://shizune.co/investors/biotech-vc-funds-canada)
- [Biotechnology Investors in Canada](https://shizune.co/investors/biotechnology-investors-canada)
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does BDC Healthcare Venture invest in?

BDC Healthcare Venture invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is BDC Healthcare Venture's check size?

BDC Healthcare Venture typically joins rounds of $8M–$68M at Series A and $4.7M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BDC Healthcare Venture participates in.

### How do I contact BDC Healthcare Venture?

Public channels for BDC Healthcare Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BDC Healthcare Venture?

The team at BDC Healthcare Venture includes Amine Benmoussa (Principal), Dion Madsen (Senior Managing Partner) and Allyson Tighe (Analyst, Healthcare Venture Fund), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co